Egland Lab

Find out how David Ure, Founder and CEO of Inanovate, Inc., came up with the idea for longitudinal assay screening by listening to his interview with South Dakota Public Broadcasting! Inanovate's longitudinal assay screening method is being used with a biomarker to detect breast cancer that was invented by Sanford researchers Kristi Egland, PhD and Rick Evans.

Innovation: Longitudinal Assay Screening David Ure, Chief Executive Officer and Founder of Inanovate. He is also the co-inventor of the Longitudinal Assay Screening technology. Inanovate, Inc. is

Kim Patrick and Dr. Kristi Egland were on KSOO radio on Sat April 13 to discuss their collaboration with Inanovate, the generation of their breast cancer blood test, and the recent $3.1 million dollar investment.
https://ksoo.com/listen-live/?fbclid=IwAR3F5F1vtbhPqdgzAQpp5OZNvlf7HxRnAoymNC9eyELim-tXr_YGV0hlPik

Kristi Egland was featured in an article in MED Magazine Midwest Medical Edition entitled, “Researcher Kristi Egland on Survival, Inspiration, and the Test That Could Revolutionize Breast Cancer Care.” Egland describes how her personal battle against breast cancer inspired her to develop a blood test for the disease.

http://www.midwestmedicaledition.com/2018/08/28/179200/researcher-kristi-egland-on-survival-inspiration-and-the-test-that-could-revolutionize-breast-cancer-care

In Print | MED MAGAZINE